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Abstract 
Background: Patients taking warfarin are at risk for thromboembolic events when not in a therapeutic international 
normalized ratio (INR) range.  Patient’s lack of understanding regarding their medication and illness often leads to 
non-adherence to medication, which can lead to adverse events. In a retrospective cohort study, the Lehigh Valley 
Physicians Group (LVPG) Anticoagulation Clinic will be able to analyze the impact of implementing a web-based 
educational application that can be accessed from the patient’s home. The objective is to educate warfarin-naïve 
patients on their treatment in order to keep patients in a therapeutic INR range and reduce the risk of adverse events.  
Methods: In a retrospective cohort study, Lehigh Valley Physicians Group (LVPG) Anticoagulation Clinic will 
provide access to web-based education to patients requiring first time treatment with the oral anticoagulant, 
warfarin. These patients will be followed for one year to capture % time in therapeutic range and the frequency of 
adverse events such as stroke, gastrointestinal bleed, deep vein thrombosis (DVT), pulmonary embolus (PE), 
myocardial infarction (MI), hospital re-admissions, and hospitalizations. Patient outcomes in the study group will be 
compared to outcomes in warfarin naïve patents that do not take part in the web-based education. Secondary 
outcomes will include patients’ perception on their quality of life, severity of anxiety and depression, their 
knowledge regarding understanding of their illness and medication prior to and after education. Surveys will be 
captured at baseline and six months. Surveys include the Palliative Outcome Scale (POS), to measure quality of life, 
Patient Health Questionnaire (PHQ-9) to assess their depression score, Generalized Anxiety Disorder 7 Item Scale 
(GAD-7) to assess their anxiety score, and Patient Activation Measure® (PAM®) which will measure the patient’s 
knowledge and perception of both their medication and illness. A community care team (CCT) will be joining 
LVPG Cardiology to assist with the management of patients with Congestive Heart Failure (CHF). Team members 
will be consulted when patients are identified in the study as having anxiety, depression, poor coping skills, a poor 
understanding of their warfarin medication, financial issues, or lack of social support at home. These patient 
outcomes will be analyzed separately to determine effectiveness of the CCT on this patient population. 
Conclusions: Both the web-based education and the CCT installment in the LVPG Anticoagulation Clinic aim to 
decrease overall hospital admissions and readmissions thereby cutting costs and satisfying the requirements for the 
Hospital Readmission Reduction Program under the Affordable Care Act. With the objective of decreasing adverse 
events, keeping patients in a therapeutic INR range, and encouraging patients to be proactive and knowledgeable in 
regards to their treatment, both the web-based education and CCT have the intention of achieving the three goals 
specified by the Triple Aim; better cost, better health, and better care.  
Introduction 
Patients with diagnoses such as atrial fibrillation, 
deep vein thrombosis (DVT), mechanical valve 
replacements, pulmonary embolus (PE), venous 
thromboembolism (VTE), myocardial infarction 
(MI), peripheral arterial occlusion, and stroke 
may require the use of anticoagulants to prevent 
the occurrence or reoccurrence of a thrombotic 
events (Johnson; “Point-of-Care International 
Normalized Ratio (INR) Monitoring Devices for 
Patients on Long-term Oral Anticoagulation 
Therapy: An Evidence-Based Analysis.,” 2009). 
Anticoagulants prevent the coagulation or 
clotting of blood. In the United States, an 
estimated 2.6 million people have atrial 
fibrillation and 900,000 VTE events occur 
annually (Mahan et al., 2012). Today there are 
numerous oral anticoagulants on the market, but 
the vitamin K antagonists (VKA) remain the 
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most popular with over 60 years of use in 
treating thromboembolic events (Yates & 
Sarode, 2015). Vitamin K antagonists act by 
reducing the action of vitamin K. Vitamin K 
antagonists need to be closely monitored due to 
their narrow therapeutic index and various food 
and drug interactions (DynaMed, 2015).	  If not 
closely managed, patients can fall outside of the 
set goal. If the INR is too high, this increases the 
patients risk of hemorrhage and if the INR is too 
low, the patent is at risk for a thromboembolic 
event (Johnson). When oral anticoagulants are 
poorly controlled, there is a significant increase 
for the risk of death, ischemic stroke and 
thromboembolic events. Approximately 90% of 
warfarin-related deaths are caused by 
intracranial hemorrhage due to complications of 
VKA oral anticoagulants (Yates & Sarode, 
2015). For patients on warfarin, the frequency of 
bleeding events is approximately between 15 
and 20% annually (Zareh, Davis, & Henderson, 
2011). However, when properly managed, oral 
anticoagulants can significantly decrease the 
frequency of stroke by more than two thirds 
(Pokorney et al., 2015).  
In North America, warfarin is the most 
commonly prescribed oral anticoagulant and is 
also frequently prescribed worldwide (Shuaib, 
Iftikhar, Alweis, & Shahid, 2014). Annually, 
there are 30 million prescriptions for warfarin 
with total direct expenditures estimated to be 
158 million dollars per quarter (Kirley, Qato, 
Kornfield, Stafford, & Alexander, 2012; 
Wysowski, Nourjah, & Swartz, 2007). Warfarin 
decreases the risk of ischemic stroke by 67% 
and death by 25% (Gladstone et al., 2009). In 
order to promote the safety and effectiveness of 
warfarin, patients need to stay in therapeutic 
range (TTR) with an international normalized 
ratio (INR) of 2.0-3.0 (Pokorney et al., 2015) or 
2.5-3.5 for mechanical mitral valves (Kardon, 
n.d.). Previous research has shown that the 
minimum time spent in therapeutic INR range 
needs to be >58% in order for warfarin to be 
effective (Smith, Xuereb, Pattison, Lip, & Lane, 
2010). Data has shown that when patients’ INRs 
are in therapeutic range for 70% of the time, 
their risk of stroke reduces by 79%, compared to 
those who spent less than 30% of their time 
within range (Gallagher, Setakis, Plumb, 
Clemens, & van Staa, 2011). When properly 
managed, warfarin is highly effective. However, 
patient adherence and knowledge of their drug 
treatment often serves as a barrier to its 
effectiveness.  
It was found that during the first three months of 
treatment for warfarin-naïve patients, that half of 
thrombotic events occurred during this time 
frame (Palareti et al., 1997). These events can be 
attributed to numerous factors, those of which 
include patient knowledge and perception of 
their condition and treatment, non-adherence to 
medication, lifestyle habits such as diet and 
alcohol consumption, and compliance (Baker, 
Pierce, & Ryals, 2011). For example, a study 
conducted by Shuaib et al. on patients’ 
knowledge of their drug regimen found that 56% 
of patients were unaware of any warfarin drug 
interactions, 70% were not acquainted with the 
term INR, and 58% were not aware of adverse 
effects (Shuaib et al., 2014). Studies have also 
shown that there is a direct correlation between 
patient knowledge and their time spent in 
therapeutic INR range (Tang et al., 2003). 
Previous research exhibits that patients managed 
in an anticoagulation clinic versus those who 
were not, spent significantly more time in 
therapeutic range (van Walraven, Jennings, 
Oake, Fergusson, & Forster, 2006). In order to 
increase adherence and decrease 
thromboembolic events, warfarin-naïve patients 
should be formally educated and closely 
monitored by an anticoagulation clinic.  
Under the Affordable Care Act, Medicare is 
authorized to decrease payments to hospitals that 
have a high percentage of hospital readmissions. 
	   3	  
The program pays specific attention to high-risk 
and high cost patients, such as those with 
pneumonia, heart attack, heart failure, chronic 
obstructive pulmonary disease (COPD), and 
hip/knee replacement (Center for Medicare and 
Medicaid Services, 2015). Readmissions are 
calculated using a ratio of hospital predicted 30-
day readmissions by the expected readmissions 
based on similar hospital averages. Medicare 
states that a high volume of readmissions can be 
attributed to inadequate care coordination and 
follow up care in the community (Center for 
Medicare and Medicaid Services, 2015). At 
Lehigh Valley Health Network, the department 
of Population Health consists of community care 
teams (CCT) who are placed in primary care 
practices that are transitioning into patient-
centered medical homes (PCMH). Community 
Care Teams consist of social workers, 
pharmacists, nurse care managers, and 
behavioral health specialists (Foltz et al., 2014). 
Community Care Teams directly manage high-
risk patients in order to increase practice 
effectiveness and efficiency as well as improve 
patient outcomes. These outcomes include 
decreased hospitalizations, patient satisfaction 
and decreased medical costs. In a study 
conducted by Foltz et al., they found that 
practices containing CCT’s reduced the 
probability of admission and readmission 
compared to those without CCT’s (Foltz et al., 
2014). By improving the quality of care, CCT’s 
help to coordinate care and reduce both 
admissions and readmissions, thus assisting in 
meeting the criteria for the Hospital 
Readmission Reduction Program under the 
Affordable Care Act (Figure 1). In the upcoming 
months, a CCT will be implemented in the 
LVPG Cardiology and to include patients seen 
in the anticoagulation clinic to manage high-risk 
congestive heart failure (CHF) patients, for now. 
If shown effective, this may expand to other 
patients with high-risk disease.  
In a study conducted by Liles et al., they found 
that at baseline, two of the most common causes 
for readmission were medication non-adherence 
and lack of patient understanding (Allen Liles, 
Moore, & Stein, 2015). Through the web-based 
education system, patients new to warfarin will 
be encouraged to stick to their medication 
regimen and be made aware of the 
thromboembolic events, which may occur as 
result of medication non-compliance. Patients 
will also be thoroughly educated on their 
condition and treatment in order to increase 
understanding in hopes of decreasing 
readmissions and adverse events. Through both 
the web-based education system and the CCT, 
the LVPG anticoagulation clinic aims to 
improve patient outcomes and decreases 
readmissions in order to ensure the highest 
quality of care encouraged under the Affordable 
Care Act. 
In a retrospective cohort study, the Lehigh 
Valley Physicians Group (LVPG) 
Anticoagulation Clinic will analyze the impact 
of implementing a web-based educational 
application system that can be accessed from the 
patient’s home and when its most convenient for 
the patient. The objective is to educate warfarin-
naïve patients on their concepts related to 
“taking warfarin” in order to reduce the risk of 
adverse events and more time spent in 
therapeutic INR range. This study will also look 
at secondary outcomes, including health-related 
quality of life, anxiety and depression scores, 
hospitalizations and readmissions, and patient 
knowledge and perception of medication and 
illness prior to and after education. 
Methods 
Study Design 
This will be a retrospective, cohort study of 
patients who are managed at the LVPG 
Anticoagulation Clinic and who are diagnosed 
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with a condition requiring first-time treatment 
with the oral anticoagulant warfarin. Study 
participants must be at least 18 years of age, 
have no cognitive deficiencies, be willing to 
participate and attend follow-up visits in the 
clinic for one year, and have no life-threatening 
illnesses with life expectancy <1 year. In order 
to complete the web-based education, patients 
must have at-home access to technology. This 
includes computers, cell phones or a tablet. 
Those without access or those who do not 
complete the education will be used as a control 
group for comparison. Patients new to warfarin 
will be sent an e-mail containing an access code 
to the web-based educational system where they 
will receive in-depth education regarding their 
treatment. If the patients do not use email, a 
letter will be generated that includes the web site 
to access the information along with an access 
code. The education consists of five (5), brief 
modules that very simply review important 
concepts on taking warfarin safely and 
effectively. The patient will have the ability to 
access and view the web-based education at 
home, at a time that is best suited for them and 
allows more time to concentrate and understand 
the concepts. Time spent in therapeutic INR 
range and the frequency of adverse events such 
as hemorrhagic or embolic stroke, 
gastrointestinal bleed, DVT, PE, MI or re-
hospitalization, of warfarin-naïve patients will 
be captured and compared between groups; 
those who receive educational intervention using 
the web-based technology compared to warfarin-
naïve patients who are not educated using the 
technology. Secondary outcomes will include 
patients’ perception on their quality of life, 
severity of anxiety and depression, their 
knowledge regarding understanding of their 
illness and medication prior to and after 
education. Surveys will be captured at baseline 
and six months. Surveys include the Palliative 
Outcome Scale (POS), to measure quality of life, 
Patient Health Questionnaire (PHQ-9) to assess 
their depression score, Generalized Anxiety 
Disorder 7 Item Scale (GAD-7) to assess their 
anxiety score, and Patient Activation Measure® 
(PAM®) which will measure the patient’s 
knowledge and perception of both their 
medication and illness.  
As part of the Patient Centered Medical Home, a 
community care team (CCT) will be joining 
LVPG Cardiology to assist with the 
management of patients with Congestive Heart 
Failure. (CHF) This team will include a social 
worker, pharmacist, nurse care manager, and a 
behavioral health specialist. The team members 
will assist in managing these high-risk patients 
in order to improve patient outcomes.  
Community Care Teams members will be 
consulted to assist with those patients identified 
in the study as having anxiety, depression, poor 
coping skills, a poor understanding of their 
warfarin medication, financial issues, or lack of 
social support at home. These patient’s 
outcomes will be analyzed separately to 
determine effectiveness of the CCT on this 
patient population.  
Materials and Procedures 
At the patient’s first visit to the LVPG 
Anticoagulation Clinic they will be provided the 
education website and a patient specific access 
code. If the patient does not have access to 
email, they will be given a letter that provides 
the web address as well as the access code. The 
web-based education system will consist of five 
modules that will be available in both English 
and Spanish and takes approximately twenty 
minutes to complete. The focus of the modules 
is to educate patients on how to safely and 
effectively take warfarin. These modules include 
videos that cover the basics of taking warfarin, 
managing your medications, monitoring 
warfarin, what can affect warfarin, and how to 
stay safe while taking warfarin. Patients will 
have the ability to watch the modules at home at 
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their leisure at a time most suitable for learning. 
If the patient has any difficulties operating 
technology or the web-based education, family 
members are encouraged to join in and assist 
with the learning process.  
During the first visit and at six (6) months, 
patients will be given the following 
questionnaires. The Palliative Outcome Scale 
(POS) questionnaire to assess their quality of life 
(QoL) The questionnaire is available in eleven 
languages and asks the patient ten questions 
regarding their disease state and how it affects 
them physically, psychologically, emotionally 
and spiritually. The scores from each question 
are totaled and the overall score represents the 
necessity for clinical attention. The 
questionnaire is most beneficial when given 
periodically over time in order to recognize any 
changes in the patients QoL that require clinical 
attention (Cicely Saunders Institute, 2012). The 
Patient Health Questionnaire (PHQ-9) to assess 
their depression score. The questionnaire 
consists of nine questions with answers ranging 
on a scale from 0-3. All checked boxes are 
added to establish the patients total score which 
is then used to determine depression severity 
(Kroenke, Spitzer, & Williams, 2001). The 
Generalized Anxiety Disorder 7 Item Scale 
(GAD-7) to assess their anxiety score. The 
questionnaire consists of seven questions that 
screen for panic disorder, social anxiety disorder 
and post-traumatic stress disorder (PTSD). 
Patients rate on a scale from 0-3 how difficult 
their daily tasks are such as work, 
communicating with others and accomplishing 
things at home. Their total score is then used to 
interpret the severity of their anxiety (Spitzer, 
Kroenke, Williams, & Löwe, 2006).  
Patient’s knowledge and perception of both their 
medication and illness will be evaluated using 
the Patient Activation Measure® (PAM®) 
score, which is available in twenty-two 
languages. Patients are scored between 0-100 
and fall into one of four levels that represent 
their activation. Level 1 patients are considered 
disengaged and overwhelmed, level 2 are 
becoming aware but still struggling, level 3 are 
taking action, and level 4 are maintaining 
behaviors and pushing further (Insignia Health, 
2015). The PAM® score helps to predict health 
behaviors and outcomes and is an indicator at 
how well patients are able to manage their 
treatment. The PAM® score will be given pre 
and post education. Those patients who do not 
complete the education will complete the Patient 
Activation Measure® pre and post first visit to 
the LVPG Anticoagulation Clinic.  
 
Endpoints 
International normalized ratios will be 
monitored during the patients visit to the LVPG 
Anticoagulation Clinic or as recommended by 
their practitioner. These INR’s can be obtained 
either at a local lab, from a home based 
monitoring device, or at the LVPG 
Anticoagulation Clinic. These INR results will 
be logged into the patient’s electronic medical 
record. As part of our analysis, all INR’s for one 
year will be captured. The goal is to keep 
patients in a therapeutic INR range of 2.0-3.0 
and 2.5-3.5 for patients with mechanical heart 
valves, or as directed by the ordering physician. 
Time spent in therapeutic INR will be calculated 
using the percent of visits in range. This is 
calculated by taking the number of visits the 
patient had INR results in range, divided by the 
total number of visits. Adverse events such as 
hemorrhagic or embolic stroke, gastrointestinal 
bleed, DVT, PE, MI or re-hospitalization will be 
measured using patients’ records through EPIC 
electronic health record software or patient 
reported information. Patients who complete the 
web-based education will be tracked through 
EPIC and logged under “other-orders.” A 
monthly report is also sent out to the director of 
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Population Health, the Advanced Practice 
Nurses in the LVPG Coumadin Clinic, and 
Lehigh Valley Health Network (LVHN) steering 
committee stating the percentage of patients who 
completed the web-based education. Results 
from the QoL, GAD-7, PHQ-9, and PAM® 
surveys will be captured and analyzed and 
reported out in percentages. 
Results 
Research shows that patients need to be in a 
therapeutic INR range for more than 58% of the 
time in order for their warfarin treatment to be 
effective (Smith et al., 2010) and data has shown 
that when patients’ INRs are in therapeutic range 
for 70% of the time, their risk of stroke reduces 
by 79%, compared to those who spent less than 
30% of their time within range. The LVPG 
Anticoagulation Clinic will measure a patient’s 
time spent in therapeutic INR range by taking 
the number of visits that the patient had INR 
results in range and dividing it by the total 
number of visits. This will allow the clinic to 
analyze the impact of the web-based education 
on patients INR’s and compare them to patients 
who did not receive the education. 
Patients can be identified as having completed or 
did not complete the web-based education via 
the EPIC electronic medical record. This will 
assist in differentiating groups.  
Adverse events will be abstracted from the EPIC 
electronic medical record. Number of 
occurrences for each adverse event will be 
compared amongst groups including the group 
who receives the education, the group with no 
education and the CHF group. 
The POS questionnaire, the PHQ-9, and the 
GAD-7will each be analyzed based on their 
scoring criteria and results will be captured and 
compared amongst groups. The PAM® score 
will be utilized to test patients’ knowledge and 
understanding of their medication and illness 
and results compared amongst groups.  
The web-based education also seeks to improve 
patient knowledge and perception of their 
medication and illness thereby increasing their 
quality of life, decreasing their anxiety and 
depression, and ensuring their safety. With the 
implementation of a CCT within the LVPG 
Anticoagulation Clinic, outcomes are expected 
to improve among the high-risk CHF patients 
whose care will be closely managed by members 
of the CCT. After the INR’s from baseline to 
one year are analyzed, the clinic will have a 
better understanding of the effectiveness of web-
based education on patients new to warfarin.   
Conclusion 
Atrial fibrillation and thromboembolic events 
are a common occurrence and effect many 
people in the Untied States. Despite the new oral 
anticoagulants on the market today, warfarin 
remains the most commonly prescribed oral 
anticoagulant. Given the narrow therapeutic 
range of warfarin, it is imperative that patients 
adhere to their medication regimen and stay 
within their therapeutic range. Patients who fall 
outside of this range are at risk for adverse 
events. Knowledge and understanding of 
warfarin and its effects can be a barrier to the 
patient’s success while taking warfarin. 
Research has shown that there is a direct 
correlation between patient knowledge and time 
spent in therapeutic range, therefore, the more 
time spent in therapeutic range, the less adverse 
outcomes. Our study sets out to determine if a 
web-based educational application that teaches 
patients new to warfarin about their illness and 
the importance of medication adherence will 
result in less adverse events.  Both the web-
based education and the CCT installment in the 
LVPG Anticoagulation Clinic aim to decrease 
overall hospital admissions and readmissions 
thereby cutting costs and satisfying the 
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requirements for the Hospital Readmission 
Reduction Program under the Affordable Care 
Act. With the objective of decreasing adverse 
events, keeping patients in a therapeutic INR 
range, and encouraging patients to be proactive 
and knowledgeable in regards to their treatment, 
both the web-based education and CCT have the 
intention of achieving the three goals specified 
by the Triple Aim; better cost, better health, and 
better care.  
References 
Allen Liles, E., Moore, C. R., & Stein, J. (2015). 
Feedback on Bounce Backs: Real-Time 
Notification of Readmissions and the Impact on 
Readmission Rates and Physician Perceptions. 
Southern Medical Journal, 108(6), 354–8. 
http://doi.org/10.14423/SMJ.000000000000028
7 
Baker, J. W., Pierce, K. L., & Ryals, C. A. (2011). 
INR goal attainment and oral anticoagulation 
knowledge of patients enrolled in an 
anticoagulation clinic in a Veterans Affairs 
medical center. Journal of Managed Care 




Center for Medicare and Medicaid Services. (2015). 
Linking Quality to Payment. 
Cicely Saunders Institute. (2012). Palliative Care 
Outcome Scale. 
DynaMed. (2015). Vitamin K Antagonist 






Foltz, C., Lawrence, S., Biery, N., Gratz, N., Paxton, 
H., & Swavely, D. (2014). Supporting Primary 
Care Patient-Centered Medical Homes with 
Community Care Teams: Findings from a Pilot 
Study. JCOM, 21(8). 
Gallagher, A. M., Setakis, E., Plumb, J. M., Clemens, 
A., & van Staa, T.-P. (2011). Risks of stroke 
and mortality associated with suboptimal 
anticoagulation in atrial fibrillation patients. 
Thrombosis and Haemostasis, 106(5), 968–77. 
http://doi.org/10.1160/TH11-05-0353 
Gladstone, D. J., Bui, E., Fang, J., Laupacis, A., 
Lindsay, M. P., Tu, J. V, … Kapral, M. K. 
(2009). Potentially preventable strokes in high-
risk patients with atrial fibrillation who are not 
adequately anticoagulated. Stroke; a Journal of 
Cerebral Circulation, 40(1), 235–40. 
http://doi.org/10.1161/STROKEAHA.108.5163
44 
Insignia Health. (2015). Patient Activation Measure 
(PAM). 
Johnson, M. P. Transitions of care in patients 
receiving oral anticoagulants: general 
principles, procedures, and impact of new oral 
anticoagulants. The Journal of Cardiovascular 
Nursing, 28(1), 54–65. 
http://doi.org/10.1097/JCN.0b013e31823776e6 
Kardon, E. (n.d.). Prosthetic Heart Valves Workup. 
Retrieved July 10, 2015, from 
http://emedicine.medscape.com/article/780702-
workup 
Kirley, K., Qato, D. M., Kornfield, R., Stafford, R. 
S., & Alexander, G. C. (2012). National trends 
in oral anticoagulant use in the United States, 
2007 to 2011. Circulation. Cardiovascular 
Quality and Outcomes, 5(5), 615–21. 
http://doi.org/10.1161/CIRCOUTCOMES.112.
967299 
Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). 
The PHQ-9: validity of a brief depression 
severity measure. Journal of General Internal 




Mahan, C. E., Borrego, M. E., Woersching, A. L., 
Federici, R., Downey, R., Tiongson, J., … 
Spyropoulos, A. C. (2012). Venous 
thromboembolism: annualised United States 
models for total, hospital-acquired and 
preventable costs utilising long-term attack 
	   8	  
rates. Thrombosis and Haemostasis, 108(2), 
291–302. http://doi.org/10.1160/TH12-03-0162 
Palareti, G., Manotti, C., DAngelo, A., Pengo, V., 
Erba, N., Moia, M., … Coccheri, S. (1997). 
Thrombotic events during oral anticoagulant 
treatment: results of the inception-cohort, 
prospective, collaborative ISCOAT study: 
ISCOAT study group (Italian Study on 
Complications of Oral Anticoagulant Therapy). 
Thrombosis and Haemostasis, 78(6), 1438–43. 
Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9423791 
Point-of-Care International Normalized Ratio (INR) 
Monitoring Devices for Patients on Long-term 
Oral Anticoagulation Therapy: An Evidence-
Based Analysis. (2009). Ontario Health 





Pokorney, S. D., Simon, D. N., Thomas, L., Fonarow, 
G. C., Kowey, P. R., Chang, P., … Peterson, E. 
D. (2015). Patients’ time in therapeutic range 
on warfarin among US patients with atrial 
fibrillation: Results from ORBIT-AF registry. 
American Heart Journal, 170(1), 141–148.e1. 
http://doi.org/10.1016/j.ahj.2015.03.017 
Shuaib, W., Iftikhar, H., Alweis, R., & Shahid, H. 
(2014). Warfarin Therapy: Survey of Patients’ 
Knowledge of their Drug Regimen. The 
Malaysian Journal of Medical Sciences  : 




Shull, J. (2015). CCT Utilization Data: All Practices. 
Lehigh Valley Health Network. 
Smith, D. E., Xuereb, C. B., Pattison, H. M., Lip, G. 
Y. H., & Lane, D. A. (2010). TRial of an 
Educational intervention on patients’ 
knowledge of Atrial fibrillation and 
anticoagulant therapy, INR control, and 
outcome of Treatment with warfarin (TREAT). 
BMC Cardiovascular Disorders, 10(1), 21. 
http://doi.org/10.1186/1471-2261-10-21 
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & 
Löwe, B. (2006). A brief measure for assessing 
generalized anxiety disorder: the GAD-7. 
Archives of Internal Medicine, 166(10), 1092–
7. http://doi.org/10.1001/archinte.166.10.1092 
Tang, E. O. Y. L., Lai, C. S. M., Lee, K. K. C., 
Wong, R. S. M., Cheng, G., & Chan, T. Y. K. 
(2003). Relationship between patients’ warfarin 
knowledge and anticoagulation control. The 




Van Walraven, C., Jennings, A., Oake, N., 
Fergusson, D., & Forster, A. J. (2006). Effect 
of study setting on anticoagulation control: a 
systematic review and metaregression. Chest, 
129(5), 1155–66. 
http://doi.org/10.1378/chest.129.5.1155 
Wysowski, D. K., Nourjah, P., & Swartz, L. (2007). 
Bleeding complications with warfarin use: a 
prevalent adverse effect resulting in regulatory 
action. Archives of Internal Medicine, 167(13), 
1414–9. 
http://doi.org/10.1001/archinte.167.13.1414 
Yates, S. G., & Sarode, R. (2015). New strategies for 
effective treatment of vitamin K antagonist-
associated bleeding. Journal of Thrombosis and 
Haemostasis  : JTH, 13 Suppl 1, S180–6. 
http://doi.org/10.1111/jth.12970 
Zareh, M., Davis, A., & Henderson, S. (2011). 
Reversal of warfarin-induced hemorrhage in 
the emergency department. The Western 














Figure 1. The number of admissions, emergencies, and readmissions, pre and post intervention by 
the Lehigh Valley Health Network Community Care Team (Shull, 2015). The graph depicts outcomes 
including hospital admissions, hospital readmissions and Emergency Department visits before and after 
management by the Community Care Team.  
 
Admission	   Emergency	   Readmission	  
Pre-­‐Engagement	   3731	   1400	   736	  
Post-­‐Engagement	   1932	   1075	   618	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